Aldoxorubicin hydrochloride
Based on 22 publication(s) in Google Scholar
Aldoxorubicin (INNO-206) hydrochloride is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin hydrochloride (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.
For research use only. We do not sell to patients.
- CAS No.: 1361563-03-2
- Formula: C37H43ClN4O13
- Molecular Weight:787.21
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Aldoxorubicin hydrochloride
More- ACS Nano. 2026 Mar 10;20(9):7928-7939. [Abstract]
- Acta Pharm Sin B. 2023 Apr;13(4):1429-1437. [Abstract]
- Sci Adv. 2019 Aug 14;5(8):eaaw6081. [Abstract]
- Small. 2023 May;19(21):e2205606. [Abstract]
- Nano Res. 08 February 2022.
- Int J Nanomedicine. 2022 Sep 20:17:4401-4417. [Abstract]
- Br J Pharmacol. 2017 Sep;174(17):2862-2879. [Abstract]
- Small Sci. 2023 Aug;3(8):2300067. [Abstract]
- Pharmaceutics. 2021 May 5;13(5):661. [Abstract]
- Bioeng Transl Med. 2022 Jul 30;8(1):e10377. [Abstract]
- ACS Biomater Sci Eng. 2026 Jun 23. [Abstract]
- Int J Mol Sci. 2023 Feb 27;24(5):4590. [Abstract]
- J Drug Deliv Sci Technol. 2020, 102048.
- Bioconjug Chem. 2025 Feb 19;36(2):190-202. [Abstract]
- Bioconjug Chem. 2023 Sep 20;34(9):1585-1595. [Abstract]
- Bioconjug Chem. 2019 Dec 18;30(12):3098-3106. [Abstract]
- ACS Med Chem Lett. 2015 Jun 22;6(8):948-52. [Abstract]
- Biotechnol J. 2020 Dec;15(12):e2000077. [Abstract]
- Patent. US20220298225A1.
- Patent. US20200376013A1.
- Oncotarget. 2018 Oct 9;9(79):34935-34944. [Abstract]
- Methods Mol Biol. 2018:1711:351-398. [Abstract]
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
IF
All Topoisomerase Isoforms
More
Biological Activity
Topoisomerase II[4]
Aldoxorubicin hydrochloride (INNO-206)? (0.27 to 2.16 μM) inhibits blood vessel formation and reduces multiple myeloma cell growth in a pH-dependent fashion[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1361563-03-2
-
Molecular Weight 787.21
-
Formula C37H43ClN4O13
-
SMILES
[H][C@@]1(O[C@H]2C[C@@](/C(CO)=N/NC(CCCCCN3C(C=CC3=O)=O)=O)(O)CC(C2=C4O)=C(O)C5=C4C(C6=C(OC)C=CC=C6C5=O)=O)O[C@@H](C)[C@@H](O)[C@@H](N)C1.[H]Cl
-
Synonyms
INNO-206 hydrochloride; DOXO-EMCH hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (22)
-
Journal Impact Factor
-
Most Recent
-
ACS Nano
A Biomimetic Microparticle Disrupting the Intracellular/Extracellular pH Homeostasis of Tumor Cells for Cancer Chemo-Immunotherapy. [Abstract]2026 Mar 10;20(9):7928-7939. PMID: 41729031 -
Acta Pharm Sin B
2023 Apr;13(4):1429-1437. PMID: 37139433 -
Sci Adv
Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy. [Abstract]2019 Aug 14;5(8):eaaw6081. PMID: 31453327
Aldoxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Sci Adv. 2019 Aug 14;5(8):eaaw6081. [Abstract]
Aldoxorubicin, Dox-SA, or Dox-CBD-SA (5 mg/kg on a Dox basis) was administered to tumor-free FVB mice via tail vein injection. Blood plasma was collected at the indicated time points.
Aldoxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Sci Adv. 2019 Aug 14;5(8):eaaw6081. [Abstract]
MMTV-PyMT tumor-bearing mice were treated with aldoxorubicin, Dox-SA, or Dox-CBD-SA (4.16 mg/kg on a Dox basis). At the indicated time points, tumors were harvested, and the amount of Dox within the tumors was quantified.
-
Small
Overcoming Non-Specific Interactions for Efficient Encapsulation of Doxorubicin in Ferritin Nanocages for Targeted Drug Delivery. [Abstract]2023 May;19(21):e2205606. PMID: 36748864 -
-
Int J Nanomedicine
Tumor Microenvironment Multiple Responsive Nanoparticles for Targeted Delivery of Doxorubicin and CpG Against Triple-Negative Breast Cancer. [Abstract]2022 Sep 20:17:4401-4417. PMID: 36164553 -
Br J Pharmacol
A novel individual-cell-based mathematical model based on multicellular tumour spheroids for evaluating doxorubicin-related delivery in avascular regions. [Abstract]2017 Sep;174(17):2862-2879. PMID: 28608595
Aldoxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Br J Pharmacol. 2017 Sep;174(17):2862-2879. [Abstract]
HSA decorated with Cy7 could be imaged. Through this strategy, the drug distribution of the HSA-decorated form and unbound form are imaged, and the merge rates are also calculated.
-
Small Sci
2023 Aug;3(8):2300067. PMID: 38465197 -
Pharmaceutics
Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer. [Abstract]2021 May 5;13(5):661. PMID: 34063098 -
Bioeng Transl Med
Nanoalbumin-prodrug conjugates prepared via a thiolation-and-conjugation method improve cancer chemotherapy and immune checkpoint blockade therapy by promoting CD8+ T-cell infiltration. [Abstract]2022 Jul 30;8(1):e10377. PMID: 36684090 -
ACS Biomater Sci Eng
MT3-KN035 Nanoparticles Based on PD-L1 Nanobodies Allow for Multiple Drug Conjugations that Promote Chemo- and Immunosynergistic Therapies. [Abstract]2026 Jun 23. PMID: 42334414 -
Int J Mol Sci
A Novel Homodimer Peptide-Drug Conjugate Improves the Efficacy of HER2-Positive Breast Cancer Therapy. [Abstract]2023 Feb 27;24(5):4590. PMID: 36902021 -
-
Bioconjug Chem
Modular Synthesis of Anti-HER2 Dual-Drug Antibody-Drug Conjugates Demonstrating Improved Toxicity. [Abstract]2025 Feb 19;36(2):190-202. PMID: 39841105 -
Bioconjug Chem
2023 Sep 20;34(9):1585-1595. PMID: 37615599 -
Bioconjug Chem
Targeting Triple Negative Breast Cancer Cells with Novel Cytotoxic Peptide-Doxorubicin Conjugates. [Abstract]2019 Dec 18;30(12):3098-3106. PMID: 31715102 -
ACS Med Chem Lett
High-Throughput Screening of Patient-Derived Cultures Reveals Potential for Precision Medicine in Glioblastoma. [Abstract]2015 Jun 22;6(8):948-52. PMID: 26288699 -
Biotechnol J
Doxorubicin-Loaded Physalis Mottle Virus Particles Function as a pH-Responsive Prodrug Enabling Cancer Therapy. [Abstract]2020 Dec;15(12):e2000077. PMID: 32918857 -
-
-
Oncotarget
Aldoxorubicin and Temozolomide combination in a xenograft mice model of human glioblastoma. [Abstract]2018 Oct 9;9(79):34935-34944. PMID: 30405885 -
Methods Mol Biol
2018:1711:351-398. PMID: 29344898
Purity & Documentation
References
[1]. Walker L, et al. Cell penetrating peptides fused to a thermally targeted biopolymer drug carrier improve the delivery and antitumor efficacy of an acid-sensitive doxorubicin derivative. Int J Pharm. 2012 Oct 15;436(1-2):825-32. [Content Brief]
[2]. Graeser R, et al. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drugs. 2010 F [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Aldoxorubicin hydrochloride Related Classifications
HY-16261C Related Classifications
Powered by Bioz